Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection

Table 1 Clinicopathological features of patients in the three alpha-fetoprotein response groups n (%)

	Total(n = 334)	Normal group(n = 178)	Response group(n = 129)	Non-response group(n = 27)	P value
Gender
Male	155 (46.41)	86 (48.31)	56 (43.41)	13 (48.15)	0.684
Female	179 (53.59)	92 (51.69)	73 (56.59)	14 (51.85)
Age (mean ± SD, yr)	58.76 ± 10.09	59.94 ± 9.56	57.56 ± 10.43	56.70 ± 11.16	0.066
HBV
No	148 (44.31)	81 (45.51)	54 (41.86)	13 (48.15)	0.749
Yes	186 (55.69)	97 (54.49)	75 (58.14)	14 (51.85)
HCV
No	274 (82.04)	151 (84.83)	103 (79.84)	20 (74.07)	0.283
Yes	60 (17.96)	27 (15.17)	26 (20.16)	7 (25.93)
Platelet × 103, median (range), n = 332	191 (14, 850)	191 (49, 850)	193 (14, 690)	155 (36, 444)	0.361
Tumor size (cm), median (range), n = 333	4.3 (0.5, 26.5)	4 (0.5, 26.5)	5.1 (0.8, 18)	4.75 (1.3, 14)	0.204
No. of tumors
Single	262 (78.44)	143 (80.34)	99 (76.74)	20 (74.07)	0.637
Multiple	72 (21.56)	35 (19.66)	30 (23.26)	7 (25.93)
mVI
No	254 (76.05)	142 (79.78)	95 (73.64)	17 (62.96)	0.116
Yes	80 (23.95)	36 (20.22)	34 (26.36)	10 (37.04)
Stage
Stage I	204 (61.08)	114 (64.04)	75 (58.14)	15 (55.56)	0.479
Stage II or higher	130 (38.92)	64 (35.96)	54 (41.86)	12 (44.44)
Resection margin n = 282
Free margin	264 (93.62)	141 (93.38)	103 (94.50)	20 (90.91)	0.808
Positive margin	18 (6.38)	10 (6.62)	6 (5.50)	2 (9.09)
Anti-viral treatment
No	179 (53.59)	92 (51.69)	71 (55.04)	16 (59.26)	0.699
Yes	155 (46.41)	86 (48.31)	58 (44.96)	11 (40.74)
Recurrence
No	181 (54.19)	103 (57.87)	69 (53.49)	9 (33.33)	0.057
Yes	153 (45.81)	75 (42.13)	60 (46.51)	18 (66.67)
Death
No	282 (84.43)	156 (87.64)	107 (82.95)	19 (70.37)	0.059
Yes	52 (15.57)	22 (12.36)	22 (17.05)	8 (29.63)
Time follow up (mo), median (range)	35.63 (0.56, 176.6)	37.96 (0.56, 130.77)	35.06 (3.76, 176.60)	14.06 (2.83, 140.93)	0.007

HBV: Hepatitis B virus; HCV: Hepatitis C virus.